The Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai is leading the movement toward diagnosis and classification of disease according to the patient’s molecular profile. This approach accommodates differences at all possible levels of exposure (genome, environment, and lifestyle) and at all stages of the process, from prevention to post-treatment follow-up.
At the center of this effort is BioMe, an electronic medical record-linked biobank that enables researchers to rapidly and efficiently conduct genetic, epidemiologic, molecular, and genomic studies on large collections of research specimens linked with medical information.
“…A potentially revolutionary new tool…Mount Sinai leads in a new era of precision medicine…”
- U.S. News and World Report, Best Hospitals, 2013 Edition
We are channeling the power of genomics and big data to elevate medical decision-making and optimize the customization of health care.
For pharmaceutical and biotech companies, drug development is multifaceted. For doctors, the administration of medical care is complex. For patients, undergoing the right treatment is decisive.
Personalized medicine is what drives our Institute's research. Help us answer the question being asked by the drug designer, the practitioner, and by patients: “Is this therapy going to work for me?”
“DNA is the key to unlocking the causes of disease and all of our own personal risks for future ailments,” says Douglas T. Dieterich, MD, Professor of Medicine, Division of Liver Diseases. “It can predict not only ours but our children’s potential problems in time to change the course of disease and history at the same time. Investing your money and your DNA in the Biobank is the best investment you can ever make in you and your family’s health.”
The World's Top 10 Most Innovative Companies in Big Data …Mount Sinai Icahn School of Medicine
For embracing data scientists and supercomputers to build the hospital of the future. …At the heart of Mount Sinai’s efforts are...BioMe, a database of genomic samples from more than 25,000 patients.”
-Fast Company, February 2014